CUPROS L (D-penicillamine) has granted the Marketing Authorization

Press Release Details

Aug 16,2023

LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for D-penicillamine (CUPROS L), CUPROS L belongs to the group of medicines called disease-modifying antirheumatic drugs (DMARDS).

Penicillamine works by reducing the body's immune response and relieving the pain, swelling, and stiffness caused by rheumatoid arthritis.

Penicillamine is also a chelating agent which means it binds to certain metals in your body, including lead and copper, to help eliminate them from the human body.

CUPROS L is a medication primarily used for the treatment of Wilson's disease. Also used for the tratment Rheumatoid arthritis, in cases of lead or other heavy metal poisoning and in cystinuria.

TIRANË-- Aug 16, 2023—LEKLI shpk. announced that the National Agency for Medicines and Medical Devices has validated the Marketing Authorization Application (MAA) for D-penicillamine (CUPROS L). The submission was supported by previously disclosed positive results of several years of work to achieve this vital formula.

ABOUT LEKLI shpk

LEKLI shpk is a pharmaceutical company focused on market research and manufacture of medical products for human use.Our experience in pharmaceuticals began in 1986 and resulted in the establishment of LEKLI shpk in 1991 by Dr. Luan Lekli. During these years, LEKLI sh.p.k managed to grow from a well- established Pharma company to a company with cross border presence.

In the following years, we specialized in the field of rare diseases, leading the market and making sure that every single patient is able to live a better life. In 2015, LEKLI sh.p.k established a production facility, manufacturing generic drugs, Phytotherapeutics and orphan drugs. To cover all the needs of the Albanian market, we produce prescription, non-prescription, extemporaneous and stock pharmaceutical preparations.

Our experience spans more than 25 years in the Balkan market, during which we have established our presence through our operations in Albania and in Kosovo. Today we have a strong brand equity and awareness. Together with our highly motivated, experienced and empowered management team we lead the market in special indications areas.

LEKLI disclaims any obligation to update the information contained in this press release as new information becomes available.

LEKLI shpk :

Kristian Lekli, +355 69 720 3644

David Lekli, +355 69 833 4620

Shpend Hasani, +383 44 197 654 (Kosove)

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.